Lectin affinity electrophoresis of serum alkaline phosphatase in metastasized breast cancer

Bricon, Thierry Le; Gay-Bellile, Cécile; Cottu, Paul; Benlakehal, Mourad; Guillon, H.; Houzé, Pascal

doi:10.1002/jcla.20357

Cited by 15 publications

(10 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The measured sensitivity and specificity for AP and ß-CTx to detect bone metastases in our study are partially contrary to results of earlier investigations: for example the sensitivity of AP is 67,0% and the specificity 100,0%, whereas ß-CTx are not able to verify the presence of bone metastases or the sensitivity/specificity of ß-CTx is only 53,0%/ 45,0% and concisely lesser than our results demonstrate [21][22][23][24].…”

Section: Discussioncontrasting

confidence: 99%

Prognostic value of bone marker beta-crosslaps in patients with breast carcinoma

Oremekn¹

2014

Integr Cancer Sci Therap

View full text Add to dashboard Cite

This study investigated the usefulness of bone markers Alkaline Phosphatase (AP) and Beta-Crosslaps (ß-CTx) to diagnose, treat and monitor patients with breast carcinoma. AP is a marker of bone formation, while ß-CTx are markers of bone resorption. ß-CTx are expressed as degradation products of collagen type I and can be measured in blood and urine. The aim of this project was to evaluate the significance of bone markers ß-CTx and AP with regard to their usage for early diagnostics of bone metastases and pathological bone metabolism in pre-and postmenopausal patients with known breast cancer. Peripheral blood samples of patients with mammarial diseases (benign and malign) were collected and the bone markers AP and ß-CTx determined. A total number of 110 patients had Benign Mammarial Diseases, BMD (30 fibroadenoma, 50 mastopathy and 30 hypertrophy patients). 30 patients were suffering from a malignant breast cancer without bone metastases. 50 patients had known bone metastases. The determination of ß-CTx was conducted based on the Immunoassay "ECLIA", the analysis approach Elecsys 2010 and cobas e by Roche Diagnostics (Mannheim, Germany). The analysis of AP was performed with the HYDRAGEL ISO-PAL kits and HYDRASYS electrophoresis system of Sebia (Fulda, Germany). For the detection of bone metastases, the study showed a sensitivity of 94.0% with 86.67% specificity for AP. Results for ß-CTx had a sensitivity and specificity of 100.0%. An elevated ß-CTx activity was associated significantly with bone metastases in the study groups (p=0.000000). Furthermore there were significant differences (p=0.000000) due to the menopausal status of patients. In conclusion ß-CTx are more sensitive and specific to detect bone metastases and bone turnover than AP. In patients with multimorbidity the origin of AP is not clear due to its multi-organic appearance. Hence ß-CTx are considered to be helpful in the diagnostic procedure of breast cancer-patients to detect bone metastases. Moreover they can be utilized to indicate patients with early dysfunctions in bone metabolism and allow inducing early treatment. ß-CTx as indicators of bone resorption, are capable to provide a significant differentiation between mamma-carcinoma patients with and without bone affection.

show abstract

Section: Discussioncontrasting

confidence: 99%

Prognostic value of bone marker beta-crosslaps in patients with breast carcinoma

Oremekn¹

2014

Integr Cancer Sci Therap

View full text Add to dashboard Cite

show abstract

“…ALP is synthesized in the liver and osteoblasts, and has been used as a specific biomarker for liver and bone. Previous studies revealed that ALP was a biomarker for the presence of bone metastases before their appearance on the bone scintigraphy [ 6 , 12 , 13 ]. In patients with BC, ALP was found to be a significant prognostic factor in bladder cancer with definitive radiotherapy [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

Serum calcium, alkaline phosphotase and hemoglobin as risk factors for bone metastases in bladder cancer

et al. 2017

View full text Add to dashboard Cite

Early detection of bone metastases is helpful for the treatment of bladder cancer (BC). In this study, we investigated the potential risk factors for bone metastasis in newly diagnosed patients with BC. A total of 902 patients diagnosed with BC between January 2000 and August 2016 were retrospectively reviewed. Of these patient, 50 (5.5%) were identified with bone metastasis. The serum levels of alkaline phosphatase (ALP) and calcium were significantly higher in patients with bone metastases than those without bone metastases (P = 0.015 and P<0.001). And the concentration of hemoglobin (HB) was significant lower in bone metastatic patients compared with non bone metastatic patients (P = 0.009). Multivariate logistic regression analysis indicated that ALP, HB and calcium were independent risk factors for bone metastases in patients with BC. The cut off values of ALP, HB and calcium were 116 U/L, 37.5g/L and 2.54 mmol/L according to the receiver operating characteristic (ROC) curves analysis. And combined ALP, HB with calcium had the highest diagnostic accuracy for predicting bone metastases in BC patients (AUC = 0.760, P<0.001). Therefore, for newly diagnosed patients with BC, the concentrations of ALP >116 U/L, HB <37.5 g/Land calcium >2.54 mmol/L were the risk factors for developing bone metastases. Combined ALP, HB with calcium was more useful to diagnose the bone metastases.

show abstract

“…1,7 Its bone-specific isoforms (bone-specific alkaline phosphatase, BAP) originates in osteoblasts that release large amounts of the enzyme when bone repair activity occurs, for example bone metastases. 8,9 In the last few decades, hundreds of studies have reported the clinical value of ALP/BAP in BC and a significant increase in serum ALP was observed, which had been demonstrated to predict bone and liver metastases. 10 Although studies have shown that ALP and BAP are predictors of metastasis and related to prognosis in BC, 3,4,[10][11][12][13] the prognostic values reported in some studies are still controversial, 11,[14][15][16][17] and no systematic review has been performed.…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of alkaline phosphatase and bone-specific alkaline phosphatase in breast cancer: A systematic review and meta-analysis

Jiang

Xia

et al. 2023

Int J Biol Markers

View full text Add to dashboard Cite

Numerous studies have reported the clinical value of alkaline phosphatase (ALP) and its bone-specific isoforms (bone-specific alkaline phosphatase (BAP)) in breast cancer. The purpose of this meta-analysis was to summarize the prognostic value of serum ALP and BAP in breast cancer, especially focused on bone metastasis and survival. PRISMA guidelines were followed to conduct this review. Observational studies were searched in PubMed, Cochcrane Library and EMBASE to January 1, 2022. Data were extracted to explore the prognostic value of ALP and BAP. The quality of the included studies was assessed and the outcome effects were evaluated. Subgroup and sensitivity analyses were performed to explore the potential sources of heterogeneity. Publication bias was assessed. There was a total of 53 studies with 22,436 patients included. For the primary outcome of survival, high levels of both ALP and BAP were associated with short survival time. The hazard ratio of high ALP level on overall survival was 1.72 (95% CI 1.37, 2.16, P < 0.001). For the secondary outcomes, a high ALP level (not BAP) was detected in breast cancer compared with healthy controls, and high levels of both ALP and BAP were risk factors for bone metastasis, while ALP (not BAP) was a risk factor for non-bone metastasis. This study showed that high levels of both serum ALP and BAP were associated with metastasis (BAP was associated with bone metastasis) and survival in breast cancer. The biomarkers could provide useful information for the early diagnostic assessment and monitoring in the follow-up of breast cancer patients.

show abstract

Lectin affinity electrophoresis of serum alkaline phosphatase in metastasized breast cancer

Cited by 15 publications

References 15 publications

Prognostic value of bone marker beta-crosslaps in patients with breast carcinoma

Prognostic value of bone marker beta-crosslaps in patients with breast carcinoma

Serum calcium, alkaline phosphotase and hemoglobin as risk factors for bone metastases in bladder cancer

Prognostic value of alkaline phosphatase and bone-specific alkaline phosphatase in breast cancer: A systematic review and meta-analysis

Contact Info

Product

Resources

About